Freya Biosciences published a paper on the development of a bacterial chassis for engineered Live Biotherapeutic Product development, featuring an E. coli Nissle 1917 derivative using tetrathionate as terminal electron acceptor for superior engraftment in an inflamed gut.

Freya Biosciences is a clinical-stage immunology company developing therapies treating inflammation and immune dysregulation in conditions that affect women. Freya is advancing a diversified pipeline, including two first-in-class Phase 2-ready assets for IVF-related embryo implantation failure and preterm birth. Freya’s science is powered by its DyscoverTM platform, a unique multi-omics data science platform built on a biobank of 1,000+ clinical samples derived from both observational and randomized, placebo controlled trials. This provides deep insights into disease pathway associated markers, allowing for de-risked target identification and patient stratification. Backed by a world-class team with a proven track record in biologics drug development, and supported by an international investor base, including Sofinnova Partners, the Gates Foundation, OMX Ventures, EIFO, and Angelini Ventures, Freya is addressing a critical gap in women's health, developing disease-modifying therapies for patients with conditions where current treatments fall short.